Tandem Diabetes faces profit strain and debt questions
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Tandem Diabetes Care has posted an 83.1% annual decline in EPS over five years despite revenue growth, alongside negative returns on capital and a high net-debt-to-EBITDA ratio. The weak profitability raises concerns the company may need to dilute shareholders to fund expansion. Analysts still expect revenue growth and a swing to profit by 2029, with some estimating 46% upside.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.